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Abstract
The purpose of this study was to assess metformin effects on high-density lipoprotein (HDL) composition of
patients with HIV-associated lipodystrophy (LDHIV). Twenty-four adult outpatients were enrolled to receive
metformin (1700 mg/d) during 6 months, but 2 were lost to follow-up and 6 stopped the drug due to adverse
events (gastrointestinal in 5, and excessive weight loss in 1). From the 16 subjects who completed the study,
69% were female. At baseline, 3 and 6 months, we assessed: weight, waist and hip circumferences, blood pres-
sure, fasting glucose and insulin, homeostasis model assessment of insulin resistance (HOMA2-IR), lipids, and
HDL subfractions by microultracentrifugation. At 0 and 6 months, body fat distribution was assessed by com-
puted tomography (CT) scan (L4 and middle femur). Metformin use was associated with reduction of mean
weight (-2.4Kg at 6 months; p  0.001), body mass index, waist, waist-to-hip ratio and a marked decrease in
blood pressure (p  0.001). Subcutaneous (p  0.01) and total abdominal fat (p  0.002) were reduced, but no
change was found in visceral or thigh fat. No difference was detected on plasma glucose, insulin, HOMA2-IR,
cholesterol or triglycerides, except for an increase in HDL3–cholesterol (from 21 mg/dL to 24 mg/dL, p  0.002)
and a reduction of nascent HDL (the fraction of plasma HDL-cholesterol not associated to subfractions HDL2
or HDL3) (p  0.008). Adverse effects were very common, but most were gastrointestinal and mild. Thus, met-
formin use in LDHIV increases HDL3–cholesterol (probably due to improved maturation of HDL) and de-
creases blood pressure, weight, waist, and subcutaneous truncal fat, making this an attractive option for pre-
venting cardiovascular disease in this population.
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Introduction
HIV-ASSOCIATED LIPODYSTROPHY (LDHIV) is a complexsyndrome characterized by body fat redistribution and
metabolic abnormalities, including insulin resistance and
dyslipidemia.1 It can be found in 40%–65% of HIV-infected
outpatients, and it seems to be strongly associated with
highly active antiretroviral therapy (HAART), in special with
protease inhibitors (PI).1,2 LDHIV is of paramount clinical
significance due to the elevated risk of cardiovascular events
observed in these patients.2
HIV-infected patients usually present reduced values of
plasma HDL-cholesterol, and after introduction of PI there
is an additional worsening in lipid profile, by reducing the
larger and more buoyant particles of HDL (-1 and -2, or
HDL2), classically known as the more cardioprotective.3
This lipoprotein profile is very similar to the one of non-
HIV–infected patients with coronary heart disease.3 Thus,
any intervention capable of improving HDL composition
could be valuable for prevention of cardiovascular disease
in these patients.
A possible way to reach that goal could be metformin, an
insulin-sensitizing agent that is reported to be useful for im-
proving HDL composition in non-HIV–infected patients
with type 2 diabetes.4 In HIV-infected patients, several stud-
ies showed that metformin reduces visceral fat accumulation
and has beneficial effects on lipid profile, insulin sensitivity,
and endothelial function, all important surrogate markers of
cardiovascular risk.5 To our knowledge, however, the effects
of metformin on HDL composition of subjects infected by
1State University of Londrina (UEL), Londrina, PR, Brazil.
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HIV have not been assessed until now. So, we conducted this
study aiming to assess HDL subfractions in patients with
LDHIV submitted to a 6-month course of metformin.
Materials and Methods
HIV-infected outpatients, aged 18 to 65 years, were se-
lected from the population followed in HIV specialized clinic
of State University of Londrina (HC/UEL). The inclusion cri-
teria were: use of HAART for at least 18 months, without
any changes in antiretroviral drugs in the previous 6 months
or during study, and presence of LDHIV. LDHIV was clini-
cally defined, requiring the detection of both the following:
(1) self-perception of body changes compatible with fat re-
distribution (central lipohypertrophy with or without lipoa-
trophy), first noticed after introduction of HAART and (2)
confirmation of these body changes at clinical examina-
tion.1,6 Patients with isolated lipoatrophy were not included,
since metformin can worsen peripheral fat loss.7 All patients
consecutively seen in HC/UEL from February to June 2006
that filled inclusion criteria were invited to participate. Ex-
clusion criteria were as follows: viral load 10,000 or more
copies per milliliter; fasting plasma glucose  126 mg/dL or
previous diagnosis of diabetes; hypertriglyceridemia  1.000
mg/dL; total plasma cholesterol  300 mg/dL; creatinine 
1.4mg/dL (female) or 1.5 mg/dL (male); liver enzymes
above 3 times normal upper limits; severe opportunistic in-
fections or active malignancy; body mass index (BMI)  18.5
kg/m2 or  30 kg/m2; congestive heart failure classes II–IV;
symptomatic chronic obstructive pulmonary disease; poor
adherence to HAART; alcohol or illicit drug abuse; current
use of glucocorticosteroids, estrogen, progesterone, anabo-
lizing agents or growth hormone; use of lipid-lowering
drugs for less than 2 months; pregnancy, and conditions that
difficult follow-up (e.g., inmates). The research was previ-
ously approved by Institutional Review Board, and all pa-
tients were voluntary and signed an Informed Consent Form.
All patients received metformin chlorhydrate (Glifage,
Merck S. A., São Paulo) during 6 months, without any ori-
entation of lifestyle changes. In the first 2 weeks, patients
took half a 850-mg tablet orally after lunch and supper (850
mg/d), and then the dosage was increased to 1 full tablet
twice daily (1.700 mg/d) until 6 months of treatment. One
visit was scheduled at 30 days in order to check adhesion to
protocol and possible adverse effects. Anthropometric mea-
surements and venous blood samples after 12 hours fasting
were collected at baseline, 3, and 6 months. An inelastic tape
was used to determine the waist circumference (dorsal de-
cubitus, at umbilical level) and hip circumference (orthosta-
tic position, at the greater trochanteres). Resting systolic and
diastolic blood pressures were determined by mercury
sphygmomanometer, in seated position, considering the
arithmetical mean of three measurements each time.
Blood samples were immediately processed in the Clini-
cal Laboratory of HC/UEL. Complete blood cell count was
performed in automated Cell Dyn 3700 (Abbott, Abbott Park,
IL), and glucose, creatinine, transaminases and lactate were
determined in automated Dimension RXL (Dade Behring,
Deerfield, IL). Women of childbearing age also had mea-
sured -HCG (Axsym, Abbott) for pregnancy exclusion.
Plasma was obtained from additional 15 mL venous blood
drawn into 0.1% tubes containing ethylenediaminete-
traacetic acide (EDTA), added the following conservatives
per milliliter: 2 mmol/L benzamidine (5 L), 0.5% gen-
tamycin and 0.25% chloramphenicol (20 L), 10 mg/mL
aprotinin (5 L), and then stored at 70°C until further anal-
ysis.
Plasma cholesterol (chol) and triglycerides (Tg) were mea-
sured with commercial kits (colorimetric-enzymatic assay,
Roche, Mannheim, Germany), and LDL-chol was calculated
by Friedewald’s formula. Plasma apolipoprotein B-100
(apoB) and apolipoprotein A-I (apoA-I) were determined by
immunoturbidimetric assay (Randox, Oceanside, CA), and
insulin by radioimmunoassay (Axsym, Abbott). Plasma
HDL-chol and Tg were measured in sobrenadant after pre-
cipitation of apoB-containing lipoproteins with phospho-
tungstic acid/MgCl2. HDL2 and HDL3 subfractions were
separated from this sobrenadant by microultracentrifugation
in Airfuge (Beckman, Fullerton, CA), carried out in Labora-
tory of Clinical Pathology, State University of Campinas
(UNICAMP).8 Chol and Tg were measured in these sub-
fractions by commercial kits (Roche) in automatized Cobas
Mira (Roche). Plasma nascent HDL-chol was calculated by:
[plasma total HDL-chol -(HDL2-chol  HDL3-chol)].
HOMA2-IR was calculated from fasting plasma glucose
and insulin, using HOMA2 Calculator For Excel, down-
loaded from: www.dtu.ox.ac.uk.9 The most recent results of
CD4 lymphocytes count (flow cytometry, Becton Dickin-
son, Franklin Lakes, NJ) and HIV viral load (reverse tan-
scriptase-polymerase chain reaction [RT-PCR], AMPLICOR
Roche) were collected from medical charts. Body fat distri-
bution was assessed by CT scan (Somatom AR Star,
Siemens), in dorsal decubitus with arms abducted above
head, at baseline, and 6 months. A 1-cm–thick slice was made
on midpoint of the femur (for thigh subcutaneous fat area
assessment), and another at L4 pedicle level (in order to as-
sess abdominal fat area: total, visceral and subcutaneous
compartments). Adipose tissue was defined by attenuation
between 50 and 250 Hounsfield units.
Statistical analysis was performed using SPSS 15.0 soft-
ware (SPSS Inc., Chicago, IL). The primary end point of the
study was the HDL2-chol/plasma total HDL-chol ratio. Nu-
meric continuous variables were compared using analysis of
variance (ANOVA) for repeated measures (general linear
model), with post-hoc analysis by least significant difference
(LSD). Student’s t test was used to compare fat areas by CT
scan. Nonparametric continuous variables were compared
by Kruskal-Wallis test, and proportions were compared by
2 (or Fisher’s exact test, when appropriate). Correlations
among CT scan fat areas and anthropometric/biochemical
data were performed by bivariate Pearson correlation. Sig-
nificance was defined as p  0.05.
Results
From 24 subjects initially assigned, 2 were lost to follow-
up and 6 discontinued metformin due to adverse effects (Fig.
1). Sixteen subjects who completed the study were included
in analysis. Two of these patients only tolerated 850mg/day,
one due to nausea and the other due to dyspepsia and pe-
ripheral fat loss. Mean age was 40 years, and most were fe-
male. Mean time since HIV diagnosis was 9.5 years, and
mean AIDS duration (defined in 75% by opportunistic in-
fection) was 8.4 years. Almost 90% had had previous or cur-
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rent PI use. All (but one) patient had CD4 lymphocytes
count above 200 cells/mm3, and 13 had undetectable ( 400
copies per milliliter) viral load at baseline. Clinical and vi-
rological data can be seen in Table 1.
Current smoking was reported by 31%, and previous
smoking by another 31%. Three (19%) reported hypertension
and 10 (62%) have previously received the diagnosis of “dys-
lipidemia,” 1 of whom used pravastatin and 2 used bezafi-
brate (all for more than 2 months). Half presented metabolic
syndrome, by NCEP-ATP III criteria.10
Lipodystrophy was first detected by the patient himself in
most cases (88%), and the majority (75%) presented mixed
lipodystrophy (central lipohypertrophy associated to lipoa-
trophy in face or limbs).
Anthropometric data at baseline, 3, and 6 months are
shown in Table 2. Mean weight loss was 1.4 kg (2.2% of ini-
tial body weight) at 3 months, and 2.4 kg (3.8% of initial
weight) at 6 months, with concomitant reduction in BMI (p 
0.001). Reduction of waist (by 2.4 cm at 3, and 4.3 cm at 6
months) and hip circumferences (1.4 cm and 2.8 cm) were
detected (p  0.001), resulting in lower waist-to-hip ratio at
6 months. A remarkable decrease was also noticed in blood
pressure at 3 months, which was sustained until 6 months;
this was more pronounced for systolic (p  0.001), but it was
also significant for diastolic and mean pressures (p  0.01).
The changes in blood pressure did not correlate with weight
or BMI (data not shown).
Baseline mean plasma glucose was 91  9 mg/dL; insulin
was 12.5  7 mU/L and HOMA2-IR was 1.6  0.9 (HOMA2-
%B: 128%  58%, HOMA2-%R: 77%  33%), with no differ-
ence from baseline to 3 or 6 months. HOMA2-IR correlated
with total abdominal (r  0.35, p  0.04) and subcutaneous ab-
dominal fat areas (r  0.37, p  0.03), but not with visceral or
thigh fat. Other correlations were found among HOMA2-IR
and BMI (r  0.47, p  0.006) and waist (r  0.39, p  0.02), but
not with body weight, hip circumference or waist-to-hip ratio.
No significant difference was detected in plasma total cho-
lesterol and its fractions (LDL, HDL), Tg, apoA-I, or apoB.
HDL2-chol and the primary outcome, HDL2-chol/total
HDL-chol, did not change as well. However, metformin use
was associated to a significant increase in HDL3-chol (p 
0.002) and a trend to increased HDL3-chol/total HDL-chol
ratio (p  0.05; Table 2). We also observed that nascent HDL-
chol (the fraction of plasma total HDL-chol in excess from
the sum of HDL2-chol and HDL3-chol) was reduced from
15% at baseline to 2% at 6 months (p  0.008; Fig. 2). No dif-
ference in lipid profile or HDL subfractions was observed
among males and females (data not shown).
CT scan showed remarkable reduction in total abdominal
adipose tissue (-10.3%) from baseline to 6 months (p  0.01).
The subcutaneous compartment was the more affected: -15%
(p  0.01). In fact, 87% of fat loss in abdomen occurred in
subcutaneous. No changes were seen in visceral abdominal
or thigh subcutaneous fat (Table 3). Abdominal total fat area
correlated well with waist circumference (r  0.70, p  0.001)
and BMI (r  0.75, p  0.001).
Total HDL-chol correlated with visceral fat area (r  0.46;
p  0.007), visceral/subcutaneous abdominal fat ratio (r 
0.60, p  0.001), and visceral/total abdominal fat ratio (r 
0.50, p  0.003). On the other hand, HDL3-chol correlated in-
versely with subcutaneous abdominal fat area (r  0.36,
p  0.03), and directly with visceral/subcutaneous fat ratio
(r  0.49, p  0.004), and with visceral/total abdominal fat
ratio (r  0.42, p  0.01). Visceral/subcutaneous fat ratio also
correlated with total chol/HDL-chol (r  0.53, p  0.002)
and LDL-chol/HDL-chol ratio (r  0.40, p  0.02).
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FIG. 1. Summary of selection process. BMI, body mass in-
dex; CRF, chronic renal failure; CHF, congestive heart fail-
ure; COPD, chronic obstructive pulmonary disease.
TABLE 1. CLINICAL AND VIROLOGIC CHARACTERISTICS OF
SUBJECTS AT BASELINE (MEAN  STANDARD DEVIATION)
n 16
Gender (M:F) 5:11
Age (years) 40.4  6.5
HIV infection known duration 113.8  31.1
(months)
AIDS duration (months) 101.4  22.0a




200 or more 7 (44%)






Duration of use of antiretroviral 
classes (months)
NRTI 96.6  21.0
NNRTI 40.1  20.0
PI 76.8  32.3
aAIDS diagnosed in 25% by CD4 cell count only.
HAART, highly-active antiretroviral therapy; NRTI, nucleoside-
analogue reverse transcriptase inhibitors; NNRTI, non-nucleoside-
analogue reverse transcriptase inhibitors; PI, protease inhibitors.
Adverse effects of metformin were quite common. Evalu-
ating all 24 subjects who initiated study, 93% of participants
reported at least one symptom (79% in first 30 days, 53% at
3 months, and 81% at 6 months). Most symptoms (78%) were
light and 21% were moderate. Most frequent complaints
were diarrhea (50% of reported symptoms), abdominal pain
(28%), nausea (24%) and dysgeusia (14%). Excessive weight
or peripheral fat loss were reported by 5 patients. No sig-
nificant change was detected in biochemical tests concern-
ing safety: complete blood count, lactate, creatinine, or
transaminases.
Discussion
This is the first study on metformin effects on HDL com-
position in LDHIV patients. These are significant data be-
cause antiatherogenic activities of HDL seem to depend on
its size and density: the larger and more buoyant the HDL
particle, the greater its efficiency in reverse cholesterol trans-
port. This difference may be at least partially due to the
higher concentration of apoA-I in lipoprotein surface.11,12
When HDL particles are fractionated by density gradient (as
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TABLE 2. ANTHROPOMETRIC DATA AND LIPID PARAMETERS AT BASELINE, THREE MONTHS, 
AND SIX MONTHS (MEAN  STANDARD DEVIATION)
Baseline 3 months 6 months pa
Anthropometric
Weight (kg) 62.3  9.5 60.9  8.9b 59.9  8.6b,c  0.001
BMI (kg/m2) 24.50  2.79 23.92  2.53b 23.58  2.6800  0.001
Waist (cm) 85.9  6.8 83.5  5.9b 81.6  5.8b,c 0.001
Hip (cm) 93.4  6.1 92.0  5.8a 90.6  5.5b,c 0.001
WHR 0.92  0.05 0.91  0.04 0.90  0.04b 0.04
SBP (mm Hg) 132.7  17.1 115.9  15.0b 117.6  12.7b0  0.001
DBP (mm Hg) 88.7  14.9 78.1  10.3b 82.3  10.10 0.007
MBP (mm Hg) 103.3  15.4 90.7  11.3b 94.1  10.6b 0.001
Lipids in total plasma
(mg/dL)
Total chol 206  42 211  380 193  3900 NS
Tg 272  167 293  200 224  8200 NS
Total HDL-chol 30.4  8.0 30.0  10.2 31.6  7.300 NS
HDL-Tg 24.87  7.52 23.38  5.830 23.25  4.7800 NS
LDL-chol 117.5  42.3 114.9  29.40 115.3  30.300 NS
ApoA-I 110.2  17.8 112.3  20.50 113.5  19.100 NS
ApoB-100 109.5  19.4 108.7  19.80 111.8  22.400 NS
Lipids in HDL2 subfraction
(mg/dL)
Chol 5.13  1.93 5.63  1.67 6.50  2.000 NS
Tg 3.88  1.71 5.50  3.31 5.00  2.420 NS
Lipids in HDL3 subfraction
(mg/dL)
Chol 20.62  6.40 21.94  5.530 24.28  6.03b,c 0.002
Tg 16.53  5.43 16.23  6.360 16.23  3.9600 NS
Relations (%)
HDL3-chol/ 67.5  10.3 76.0  12.6 76.7  7.100 0.05
total. HDL-chol
aANOVA for repeated measures.
bp  0.05 compared to baseline (ANOVA).
cp  0.05 compared to 3 months (ANOVA).
BMI, body mass index; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure;
chol, cholesterol; Tg, triglycerides; apoA-I, apolipoprotein A-I; apoB-100, apolipoprotein B-100; NS, non-significant.
FIG. 2. Relative (%) mean contributions of HDL2–choles-
terol, HDL3–cholesterol and nascent HDL-cholesterol for to-
tal plasma HDL-cholesterol, at baseline, 3 months, and 6
months. *p  0.05 compared to baseline (analysis of variance
[ANOVA] for repeated measures). HDL, high-density
lipoprotein.
in ultracentrifugation), two subpopulations can be readily
distinguished: the larger and less dense HDL2 (containing
apoA-I), and the smaller and more dense HDL3 (containing
apolipoprotein A-I and A-II).13 In our patients, a 6-months
course of metformin was associated with an increase in
HDL3–cholesterol and no change in HDL2–cholesterol.
These results are opposite to studies with non-HIV–infected
subjects with type 2 diabetes mellitus, in whom metformin
use increases the HDL2/HDL3 ratio, primarily by reduction
of HDL3-cholesterol.4
Despite some common features among LDHIV and type
2 diabetes (e.g., disturbed lipid metabolism, insulin resis-
tance and high cardiovascular risk), biological mechanisms
of dyslipidemia may be different between these two syn-
dromes. In diabetes, low HDL, high TG and increased small-
dense LDL result from lack of insulin action on key enzymes
like lipoprotein-lipase.14–17 In HIV-infected patients, other-
wise, HDL is reduced even before antiretroviral therapy,3,18
with further reduction in HDL particle size when protease
inhibitors are introduced,3,19 generating a lipid profile very
similar to that reported in non-HIV–infected subjects with
coronary heart disease.20 Insulin resistance alone is an un-
likely explanation for this lipid disturbance in our patients,
once they presented fairly normal indices of insulin action
(mean HOMA2-IR 1.6; normal is 2.7),21 which did not
change during the study. This contrasts with several studies
that reported improvement in insulin sensitivity of HIV-in-
fected subjects with metformin7,22–24; only one paper re-
ported no change.25 While most studies used HOMA-IR, we
preferred a more accurate index of insulin sensitivity
(HOMA2-IR, “computer model”), which incorporates non-
linear solutions that the older HOMA-IR equation only ap-
proximates to.26,27 Other difference from this study to the
others is that we excluded more insulin-resistant subjects
(obese and diabetic).
Other intriguing effect of metformin in our study was the
reduction of HDL-chol not contained in the HDL2 or HDL3
subfractions (Fig. 2). Indeed, we observed that the sum of
[HDL2-chol  HDL3-chol] was always lower than the total
HDL-chol measured in plasma. This third nonmeasured
HDL subfraction is very probably composed by immature
particles of HDL particles (nascent HDL), which present
higher density (1.21 g/mL) and pre- motility in immu-
noelectrophoresis, rich in apolipoprotein-A1 and phospho-
lipids.20,28 The reduction observed in nascent HDL-chol, with
concomitant increase in HDL3–chol, is compatible with an
improved maturation of smaller lipid-poor pre- HDL par-
ticles into larger lipid-enriched -2 or -3 (HDL3) particles.
Our HIV patients presented low plasma HDL-chol (mean
30 mg/dL), from which only approximately 20% were com-
posed by HDL2 (compared to approximately 30% in general
population).29 This lipid disturbance may be induced either
by effects of virus itself, or by direct effects of antiretroviral
drugs (protease inhibitors can inhibit hepatic lipase), or by
acute-phase reactants and cytokines.1,3,30 Similar HDL re-
duction has been reported in systemic inflammatory condi-
tions, like sepsis, where it is due to severe impairment of
lecithin:cholesterol acyltransferase (LCAT) activity.31,32 Inhi-
bition of LCAT is strongly related to plasma concentrations
of proinflammatory cytokines, as interleukin-2, interleukin-
6 and transforming growth factor (TGF)-.33,34 Another
model of systemic inflammation is polycystic ovary syn-
drome (PCOS), a condition in which inflammatory markers
(C-reactive protein, endothelial adhesion molecules) are
higher and HDL-cholesterol is lower and lipid-depleted,
compared to non-PCOS women.35,36 Interestingly, met-
formin use in women with PCOS was associated to reduc-
tion of these inflammatory markers.35 Thus, the improve-
ment of HDL maturation (reduction of nascent HDL-chol
and elevation of HDL3–chol) observed in our patients, also
likely affected by low-grade chronic systemic inflammation
(by LDHIV and HIV infection itself), could be due to im-
proved action of LCAT mediated by metformin, an effect al-
ready demonstrated in animal models.37
The clinical significance of HDL3 elevation is uncertain.
Evidences of cross-sectional 20 and prospective studies38–42
suggest that concentrations of the larger and less dense par-
ticles of HDL (HDL2) are more powerful predictor of car-
diovascular risk, but considerable controversy still remains.
One reason is the great heterogeneity of methods used to as-
sess HDL composition (ultracentrifugation, electrophoresis,
chromatography, spectroscopy by magnetic resonance),
which prevents comparisons among the studies.20,43,44 Asz-
talos et al.20 concluded that the association between HDL
subfractions and cardiovascular risk depends on the method-
ology adopted. To date, four prospective studies evaluated
HDL2 and HDL3 levels by ultracentrifugation and their as-
sociation with cardiovascular risk. All four showed an in-
creased risk of ischemic events with both reduced HDL2 and
HDL3.38–41 In two of them, HDL2 was more strongly related
to cardiovascular disease,39,41 while in the other two, HDL3
was better correlated.38,40 The largest of these studies was
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TABLE 3. ADIPOSE TISSUE AREAS IN DIFFERENT BODY COMPARTMENTS, AS ASSESSED BY CT
SCAN, AT BASELINE AND SIX MONTHS (MEANS  STANDARD DEVIATIONS)
Adipose tissue area (cm2) Baseline 6 months pa
Total abdominal 271.6  94.66 243.5  79.36 0.01
Visceral abdominal 107.4  51.66 103.9  58.06 NS
Subcutaneous abdominal 164.2  82.66 139.6  72.96 0.002
Subcutaneous thigh 62.0  55.4 51.4  52.5 NS
Visceral/total abdomen 0.414  0.198 0.447  0.221 0.02
Subcutaneous/total abdomen 0.585  0.198 0.553  0.221 0.02
aPaired student’s t test.
CT, computed tomography; NS, not significant.
Quebec Cardiovascular Study, in which subjects with higher
levels of HDL2 (first quartile) had 79% lower risk of cardio-
vascular events in follow-up, compared to the lower quar-
tile. In the same study, however, subjects in the higher quar-
tile of HDL3 also showed a 63% reduction in cardiovascular
risk, compared to subjects in lower quartile.41 Other actions
of HDL besides reverse cholesterol transport may also be im-
portant for cardioprotection. A recent study compared HDL2
and HDL3 particles with respect to their antioxidant activ-
ity and concluded that this activity was more evident in
HDL3.43
Beyond lipids, other noteworthy effects of metformin were
detected in our study, as a marked decrease in blood pres-
sure (also shown in previous studies),22 along with reduc-
tions in weight, waist, hip circumference, waist-to-hip ratio,
and subcutaneous abdominal fat. Other studies on met-
formin in HIV reported different patterns of fat loss on CT
scan. Most reported decrease in visceral fat, either alone7,22
or combined with subcutaneous abdominal fat,5 or no
change at all.23,25 However, all studies were limited by small
sample sizes (from 18 to 26), and subjects were different:
many included only hyperinsulinemic subjects,7,22,23 and one
study included only men.5 In our group, subcutaneous ab-
dominal fat correlated better than visceral with insulin sen-
sitivity parameters (HOMA2-IR, total chol/HDL-chol and
LDL-chol/HDL-chol ratio). The importance of subcutaneous
abdominal adipose tissue in glucose metabolism has been
previously demonstrated by studies using euglycemic
clamp.45–47
All these effects on surrogate markers like blood pressure,
BMI and waist could render metformin an attractive option
for prevention of cardiovascular disease in LDHIV patients.
However, clinical consequences of HDL3–chol increase, as
well as the impact of the drug on hard outcomes (cardio-
vascular death and/or myocardial infarction) still need be
clarified by long-term prospective studies.
Despite its potential benefits, metformin presented com-
mon adverse effects, mainly gastrointestinal (diarrhea, nau-
sea and abdominal pain), predominantly self-limited and
mild. However, one quarter of patients who started proto-
col discontinued metformin because of side effects. Loss of
peripheral fat was another common complaint, reinforcing
recommendations for caution in subjects with significantly
evident lipoatrophy.1,7,25 No serious adverse effect, like lac-
tic acidosis (reported with concomitant use of metformin and
nucleoside reverse transcriptase inhibitors),48 anemia, or he-
patotoxicity was observed.
Considering these common adverse events, perhaps met-
formin should be reserved to patients with HIV with higher
cardiovascular risk. Several clinical tools are available for
risk stratifying, as the Framingham score and the PROCAM
and SCORE equations, but it is still unknown which of these
better applies to HIV-infected subjects. However, the Fram-
ingham identified more male patients with moderate and
less with low cardiovascular risk in comparison to the other
two scores, in a recent report.49
Some limitations of our study should be considered, as the
small sample size and the lack of controls. However, we be-
lieve this should not compromise our results, since most pa-
tients were using HAART for more than 8 years, with no re-
cent changes in antiretroviral drugs, with adequate viral
suppression; in this situation, treatment-related metabolic or
morphologic disturbances should have already reached a
new equilibrium. Also, we did not assess other potential
markers of cardiovascular risk, on which metformin dem-
onstrated improvement on previous reports: tPA, PAI-1,7,50
MCP-1, paraoxonase-1,24 and flow-mediated vasodilatation
(FMD) of brachial artery.5
In conclusion, metformin use in LDHIV patients was as-
sociated with significant increase in HDL3–cholesterol and
reduction of immature forms of HDL, reflecting an improved
maturation of HDL particles, possibly due to facilitated ac-
tion of LCAT. Along with other effects (decreases of blood
pressure, body weight, waist, and subcutaneous abdominal
fat), this could suggest a preventive role of metformin against
cardiovascular disease in LDHIV patients, which needs to be
confirmed by further research. In the meanwhile, physicians
who treat HIV-infected subjects should be aware of the com-
mon adverse effects of metformin, specially gastrointestinal
symptoms and worsening of lipoatrophy.
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